Announcements Trials
Browse Landscape

Phase

Phase 3 5

Status

Active not recruiting 4Completed 1

Sponsor Class

INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

Thoracic 5Gastrointestinal 3Gynecologic 2Genitourinary 2

Conditions

Small Cell Lung Carcinoma 2Carcinoma, Non-Small-Cell Lung 2Carcinoma 2Non Small Cell Lung Cancer NSCLC 1Lung Neoplasms 1

Interventions

Pemetrexed 22Carboplatin 22Cisplatin 19Paclitaxel 9Gemcitabine 9pembrolizumab 8osimertinib 7Nivolumab 6Crizotinib 6durvalumab 5atezolizumab 5amivantamab 4Ipilimumab 4Docetaxel 4Afatinib 4tremelimumab 3lazertinib 3Vinorelbine 3Gefitinib 3Etoposide 3Albumin-Bound Paclitaxel 3trametinib 2selpercatinib 2lorlatinib 2larotrectinib 2dabrafenib 2cemiplimab 2binimetinib 2alectinib 2PM 01183 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Has announcements × durvalumab × Thoracic × Clear all
NCT03043872 2026-04-22

CASPIAN

AstraZeneca

Phase 3 Active not recruiting
987 enrolled 42 charts 1 FDA
Thoracic

Small Cell Lung Carcinoma

NCT03164616 2026-03-13

POSEIDON

AstraZeneca

Phase 3 Active not recruiting
1,186 enrolled 26 charts 1 FDA
Thoracic

Non Small Cell Lung Cancer NSCLC

NCT03703297 2025-11-21

ADRIATIC

AstraZeneca

Phase 3 Active not recruiting
730 enrolled 19 charts 1 FDA
Thoracic

Carcinoma, Lung Neoplasms, Small Cell Lung Carcinoma

NCT03800134 2025-06-11

AEGEAN

AstraZeneca

Phase 3 Active not recruiting
825 enrolled 1 FDA
Thoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung

NCT02125461 2023-10-10

PACIFIC

AstraZeneca

Phase 3 Completed
713 enrolled 23 charts 1 FDA
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡